



# A GLOBAL CANNABIS COMPANY

May 2018



## DISCLAIMER

The information found herein, and any other materials provided by Harvest One Cannabis Inc. (the “Company”), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation. This information is confidential and should not be distributed, in whole or in part, beyond the recipient and its advisors.

The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and information provided by unaffiliated third parties and is subject to change without notice.

This document may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward- looking statements are not guarantees of future performance.

All forward- looking information contained herein are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

\*All currency amounts are in Canadian dollars unless stated otherwise.

# AT A GLANCE



Licensed Producer




Medical and Pharmaceutical




Consumer Products



Clinical Trials



# OUR GLOBAL FOOTPRINT





HARVEST ONE





# DUNCAN FACILITY



## Current Profile

- ✓ ACMPR Licenses: Cultivation 2016, Sale 2017
- 🏠 State of the art 16,000 sq ft production facility
- 📦 1,000 kg annual production capacity
- 🧪 Full in-house biochemical QA/QC laboratory
- 🌿 31 distinct commercial varieties
- 🔒 Level 9 security vault
- 📈 ~\$10+ million in capital investments to date

## Expansion Plans

- 🏢 16,000 sq ft expansion
- 🌱 10,000 sq ft propagation facility
- 🧪 Advanced extraction capabilities
- 🧴 Cutting edge R&D laboratory
- 📦 Streamlined in-house packaging and processing



# FACILITY EXPANSIONS 2018



**Targeting 20,000kg capacity per year by YE 2018**

## LUCKY LAKE

- 100% owned by Harvest One
- 60,000 ft<sup>2</sup> on 18 acres site
- 12,000 kg/y production capacity
- Final stages of licensing with Health Canada
- Previous capital investment ~\$12m, H1 acquired for \$750k
- 20 ft. bay ceilings allowing multiple levels.
- Adjacent to CN rail line and airport
- Ample power and water supply
- Exceptional future development

## 2nd BC SITE

Approximately 59,000 ft<sup>2</sup> facility

Additional 20 acres available on site for expansion

Suitable for multiple levels of cultivation

Minimum 8,000+ kg/y production capacity

Ample power on site

Excellent infrastructure in place- adjacent to all major transportation links



# OUR CURRENT FACILITIES



DUNCAN

LUCKY LAKE

OUTDOOR SITE

2ND BC SITE



**HARVEST ONE**



# OUTDOOR GROWTH POTENTIAL



## FUTURE LOW COST GROWTH

- 398 acres of prime agricultural land in a unique geographical location
- Planning for potential regulatory changes to allow outdoor growing
- Potential harvest of 50,000kg in September 2019
- International outdoor growing consultants already engaged
- Potential lowest production costs in Canada



**HARVEST ONE**



**HARVEST ONE**





# JURISDICTIONS



**HARVEST ONE**

**Satipharm** is focused on near-term growth and distribution throughout the EU and in Australia. The company is concurrently preparing to import its products into Canada.

## EUROPE

- Near-term growth - significant distribution network established across Europe with long term contracts with leading pharma chains - rapidly increasing sales.
- Pharmaceutical Central Numbers (PZN codes) were obtained for 10MG and 50MG capsules in early 2017 enabling both products to be sold in any pharmacy across Germany.
- “Free Sale Certificate” as Nutritional Supplement obtained from **German** authorities, removing all barriers to trade within **EU and other jurisdictions**.

## AUSTRALIA

- One of the first ever medical cannabis products available to prescribed users in Australia.

## CANADA

- Import application submitted to Health Canada to import capsules to Canada to be sold under United Greeneries ACMPR License - anticipated to be a strong near term revenue generator.
- Further expansion plans include the introduction of other formulations including THC and importation into targeted international markets such as Canada and Australia.

# CLINICAL TRIALS - PHASE 2



Study	PTL201: Pain & Spasticity	PTL101: Paediatric Refractory Epilepsy
Study Description	A double-blind, randomized, placebo-controlled, parallel-group study of oral PTL201 THC/CBD capsules in subjects with symptoms of pain & spasticity due to MS	Open-label, single-center clinical study of oral administration of PTL101 as an adjunctive treatment to refractory epileptic children
Drug Description	Gelpell® capsules containing THC and CBD	Gelpell® capsules containing highly purified, concentrated CBD
Objective	Safety, tolerability and efficacy	Safety, tolerability and efficacy
Subjects	~70 MS patients	~15 pediatric patients with refractory epilepsy
Duration	Initiated Q2 2017	Initiated 2017- Completed YE 2018



**HARVEST ONE**

**DREAM  
WATER<sup>®</sup>**





# OUR BRANDS

## DREAM WATER®



## HARVEST ONE

### OVERVIEW

The recent acquisition of Dream Water Products Global places Harvest One at the forefront of the all important sleep and relaxation categories.

The brand is growing rapidly in Canada and the United States with over 30,000 current retail doors and plans to reach 100,000 by 2020.

Dream Water is in the process of launching an international licensing and distribution division that Harvest One expects to expand rapidly over the next 2 years.

The brand's current SKU line-up allows for immediate international expansion with non-cannabis related products to gain brand and distribution footholds in other countries where legislation will take time to allow for Cannabis based products to be sold legally.

### SKU DEVELOPMENT

- ✓ The natural sleep and relaxation categories are among the fastest growing OTC and Rx categories globally. Dream Water management is targeting \$50M in revenues by 2021
- ✓ Harvest One and Dream Water recognized the opportunity to build multiple line extensions with Dream Water branded CBD and THC infused products.
- ✓ Presently we know of no other Cannabis company with a sleep strategy that already has Dream Water's widespread brand recognition and consumer acceptance with 30,000+ retail outlets moving daily volume.
- ✓ Dream Water was voted Canada's Product of the Year for the Wellness Innovation category in 2017 and was awarded 'Best in Show' among 20 other category winners by Chatelaine magazine.



# CANNABIS FOCUSED

## POTENTIAL SKU EXTENSIONS – SLEEP, SPORT AND BEAUTY



DreamWater **CBD** Snoozeberry,  
Sleepy Citrus & Night Time  
Nectar



Dream Water  
Snoozeberry **CBD**  
Gummy/Edible



Dream Water  
Snoozeberry **CBD** Spray



Dream Water Sleepy  
Citrus **CBD** Gummy/Edible



Dream Water Sleepy  
Citrus **CBD** Spray



Dream Water Night Time  
Nectar **CBD** Gummy/Edible



Dream Water Night Time  
Nectar **CBD** Spray



Dream Water **CBD**  
Snoozeberry Powder  
( 10 pack & 5 pack)



DreamWater **CBD**  
Sport



Dream Water Sport **CBD**  
Gummy/Edible



Dream Water Sport  
**CBD** Spray



Dream Water **CBD**  
Beauty



Dream Water Beauty  
**CBD** Gummy/Edible



Dream Water  
Beauty **CBD** Spray



# FINANCIAL INFORMATION

## CAPITAL STRUCTURES

Market Capitalization	\$150 million
Issued Shares	176,168,094
Warrants	33,356,632 (\$1.00 -\$2.30)
Options	7,680,000 @ \$0.75
Cash	\$62 million
Debt	No Debt
52 week Low/High	\$0.47 – \$2.20
Insider Holdings	Approx. 30% (MMJ Holding)


## RECENT HIGHLIGHTS

- On December 14, 2017, Harvest One closed a bought deal debenture offering of \$20,125,000
- On January 31<sup>st</sup>, 2018, Harvest One announced it successfully closed \$40,250,000 public financing of Units, including exercise of over-allotment option in full.
- On April 5<sup>th</sup>, 2018 Harvest One Converts all Outstanding Debentures to Ordinary Shares and Maintains \$80m Cash Position
- On May 3<sup>rd</sup>, 2018 Harvest One completes the acquisition of Dream Water Global for approximately \$34.5m in cash and shares




# CURRENT CASH POSITION 62M+

(FURTHER \$50M+ AVAILABLE ASSUMING FULL WARRANT CONVERSION)



\* Pending regulations





# ACHIEVEMENTS & MILESTONES

## 2019

Q1

- Closed \$40m bought financing - \$80m cash in bank
- Launched retail brands
- Advanced expansion plans at 2nd BC site and Lucky Lake
- Positive Phase 2 Clinical Trials Results
- Expanded Satipharm sales in EU & Australia

Q3

- Pursue Dream Water international expansion
- Continue build out of expansion sites
- Continue site preparation for Outdoor Growing
- Increase Global Satipharm Sales including Canada (Subject to regulatory approval)
- Commence recreational sales

Q2

- Continue construction of prefabricated modules
- Complete Strategic Acquisition of Dream Water and integrate under H1
- Phase 2 Clinical Trials Results expected
- Commence site preparation for Outdoor Growing
- Commence provincial supply negotiations

Q4

- Commence cultivation in Lucky Lake
- Complete build out of Lucky Lake
- Initiate Dream Water product development

- 20,000+kg/y dried flower production
- Several provincial supply agreements in place
- Start Outdoor Growing targeting 50,000kg/y
- Satipharm sales on 3 continents – Europe, North America and Australia
- Two separate clinical Phase 2 trials published-market leader in CBD capsules
- New Dream Water product development in place and sales increasing across N. America and Europe





# ANALYST COVERAGE

FIRM	ANALYST	PHONE	EMAIL
Haywood Securities	Neal Gilmer	+1 (416) 507-2300	ngilmer@haywood.com
Mackie Research	Greg McLeish	+1 (416) 860-7600	gmcleish@mackieresearch.com





# THANK YOU

## INVESTOR RELATIONS

For more information about Harvest One, please contact:

**Colin Clancy**  
Investor Relations  
+ 1 (877) 915-7934  
[cclancy@mmj.ca](mailto:cclancy@mmj.ca)

